Immuneering Corp (IMRX)
1.53
+0.11
(+7.75%)
USD |
NASDAQ |
May 01, 16:00
1.54
+0.01
(+0.65%)
After-Hours: 20:00
Immuneering Total Liabilities (Quarterly): 12.01M for Dec. 31, 2023
Total Liabilities (Quarterly) Chart
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 12.01M |
| September 30, 2023 | 9.863M |
| June 30, 2023 | 9.791M |
| March 31, 2023 | 9.907M |
| December 31, 2022 | 12.52M |
| September 30, 2022 | 11.80M |
| June 30, 2022 | 8.455M |
| Date | Value |
|---|---|
| March 31, 2022 | 8.391M |
| December 31, 2021 | 10.72M |
| September 30, 2021 | 5.749M |
| June 30, 2021 | 88.23M |
| March 31, 2021 | 3.282M |
| December 31, 2020 | 60.90M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
3.282M
Minimum
Mar 2021
88.23M
Maximum
Jun 2021
19.36M
Average
9.907M
Median
Mar 2023
Total Liabilities (Quarterly) Benchmarks
| Geron Corp | 146.13M |
| SELLAS Life Sciences Group Inc | 14.20M |
| Elicio Therapeutics Inc | 15.77M |
| Vistagen Therapeutics Inc | 7.783M |
| ADMA Biologics Inc | 193.98M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 102.58M |
| Shareholders Equity (Quarterly) | 90.58M |